Clinical Trial Update: Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluates venetoclax combined with ASTX727 (oral decitabine/cedazuridine) in treatment-naive high-risk myelodysplastic syndrome or ch…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome
• Myelomonocytic Leukemia

Drugs mentioned

• ASTX727 (cedazuridine/decitabine)
• Venclexta (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING